AbbVie Return on Tangible Equity 2010-2023 | ABBV
Current and historical return on tangible equity values for AbbVie (ABBV) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| AbbVie Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2023-12-31 |
$4.86B |
$-77.51B |
-6.04% |
| 2023-09-30 |
$6.51B |
$-78.57B |
-7.97% |
| 2023-06-30 |
$8.69B |
$-82.19B |
-10.44% |
| 2023-03-31 |
$7.59B |
$-83.77B |
-8.93% |
| 2022-12-31 |
$11.84B |
$-82.31B |
-13.69% |
| 2022-09-30 |
$13.41B |
$-84.42B |
-15.04% |
| 2022-06-30 |
$12.64B |
$-89.16B |
-13.73% |
| 2022-03-31 |
$12.48B |
$-89.97B |
-13.20% |
| 2021-12-31 |
$11.54B |
$-92.89B |
-11.90% |
| 2021-09-30 |
$7.53B |
$-96.18B |
-7.57% |
| 2021-06-30 |
$6.66B |
$-99.14B |
-6.60% |
| 2021-03-31 |
$5.16B |
$-99.91B |
-5.04% |
| 2020-12-31 |
$4.62B |
$-102.90B |
-5.27% |
| 2020-09-30 |
$7.38B |
$-102.16B |
-10.18% |
| 2020-06-30 |
$6.96B |
$-104.40B |
-12.06% |
| 2020-03-31 |
$8.44B |
$-41.18B |
-19.73% |
| 2019-12-31 |
$7.88B |
$-42.43B |
-18.10% |
| 2019-09-30 |
$3.26B |
$-42.80B |
-7.35% |
| 2019-06-30 |
$4.12B |
$-44.67B |
-9.17% |
| 2019-03-31 |
$5.36B |
$-44.28B |
-11.85% |
| 2018-12-31 |
$5.69B |
$-45.34B |
-12.92% |
| 2018-09-30 |
$7.57B |
$-45.26B |
-17.90% |
| 2018-06-30 |
$6.45B |
$-45.97B |
-16.02% |
| 2018-03-31 |
$6.38B |
$-39.56B |
-16.68% |
| 2017-12-31 |
$5.31B |
$-38.25B |
-13.92% |
| 2017-09-30 |
$6.65B |
$-37.23B |
-17.26% |
| 2017-06-30 |
$6.62B |
$-38.01B |
-17.06% |
| 2017-03-31 |
$6.31B |
$-39.12B |
-16.14% |
| 2016-12-31 |
$5.95B |
$-39.68B |
-16.37% |
| 2016-09-30 |
$6.08B |
$-38.30B |
-18.05% |
| 2016-06-30 |
$5.72B |
$-39.32B |
-18.36% |
| 2016-03-31 |
$5.48B |
$-28.14B |
-19.40% |
| 2015-12-31 |
$5.14B |
$-28.93B |
-22.76% |
| 2015-09-30 |
$2.82B |
$-28.20B |
-16.79% |
| 2015-06-30 |
$2.08B |
$-27.64B |
-19.94% |
| 2015-03-31 |
$1.82B |
$-5.64B |
-43.02% |
| 2014-12-31 |
$1.77B |
$-5.63B |
-48.51% |
| 2014-09-30 |
$3.71B |
$-2.90B |
-117.20% |
| 2014-06-30 |
$4.17B |
$-2.72B |
-115.94% |
| 2014-03-31 |
$4.14B |
$-3.38B |
-101.41% |
| 2013-12-31 |
$4.13B |
$-3.68B |
-90.68% |
| 2013-09-30 |
$4.54B |
$-4.62B |
-92.54% |
| 2013-06-30 |
$5.16B |
$-4.66B |
-262.55% |
| 2013-03-31 |
$5.36B |
$-5.26B |
-10258.37% |
| 2012-12-31 |
$5.28B |
$-5.09B |
257.66% |
| 2012-09-30 |
$4.89B |
$7.15B |
120.78% |
| 2012-06-30 |
$3.32B |
$2.99B |
146.66% |
| 2012-03-31 |
$3.59B |
$3.14B |
237.01% |
| 2011-12-31 |
$3.43B |
$2.92B |
469.95% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$296.212B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
